In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder
Sharafshah A, Lewandrowski K, Gold M, Fuehrlein B, Ashford J, Thanos P, Wang G, Hanna C, Cadet J, Gardner E, Khalsa J, Braverman E, Baron D, Elman I, Dennen C, Bowirrat A, Pinhasov A, Modestino E, Carney P, Cortese R, Fiorelli R, Schmidt S, Pollack A, Badgaiyan R, Blum K. In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder. Current Neuropharmacology 2025, 23: 974-995. PMID: 39865816, PMCID: PMC12174944, DOI: 10.2174/011570159x349579241231080602.Peer-Reviewed Original ResearchGenetic Addiction Risk ScoreSubstance use disordersReward Deficiency SyndromeAlcohol use disorderSuicidal ideationDepressive phenotypeGlucagon-like peptide-1Use disorderAnti-addictive compoundsGLP1R agonistsAntiaddictive effectsDopamine signalingDopaminergic signalingGlucagon-like peptide-1 agonistsRisk scoreDopamine regulationDopamine homeostasisGlucagon-like peptide-1 receptorEmpirical clinical studiesPeptide-1 receptorIdeationDeficiency syndromeDisordersLong-term inductionTherapeutic advantage
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply